Tri-Trenbol Trenbolone Blend 250 mg/ml

• Category: Injectable anabolic–androgenic steroid blend – Research Only
• Brand: Royal Pharmaceuticals
• Total Strength: 250 mg/ml trenbolone esters
• Ester Breakdown: 70 mg Acetate + 130 mg Enanthate + 50 mg Hexahydrobenzylcarbonate
• Packing: 10 1 ml ampoules
• Origin: United Kingdom
• Research Use: For analytical, laboratory and in-vitro experimentation. Not a medicine or dietary supplement.

What Is Tri-TrenBol?

Tri-TrenBol combines three trenbolone esters into a single oil-based depot solution:

• Trenbolone Acetate – 70 mg/ml (short-acting ester)
• Trenbolone Enanthate – 130 mg/ml (medium/long-acting ester)
• Trenbolone Hexahydrobenzylcarbonate – 50 mg/ml (long-acting Parabolan-type ester)

All three are prodrugs that release the same active steroid, trenbolone, a potent 19-nor androgen used in research for AR binding, anabolic modelling, pharmacokinetics and doping-analysis reference.

Mechanism of Action

1. Prodrug Activation

Each ester is cleaved by esterases, releasing free trenbolone plus the corresponding acid (acetic, enanthic, hexahydrobenzyl).

2. Androgen Receptor (AR) Agonist

Trenbolone binds strongly to AR, promoting:

• Enhanced protein synthesis
• High nitrogen retention
• Increased red blood cell production
• Reduced glucocorticoid signalling

3. Non-aromatising, Progestogenic Profile

Trenbolone does not aromatise to estradiol and exhibits notable progestogenic activity, relevant in endocrine feedback research.

4. Multi-phase Release

• Acetate: ~1–3 day effective half-life
• Enanthate: ~7–10 days
• Hexahydrobenzylcarbonate: ~8–11 days

This creates overlapping peaks, ideal for pharmacokinetic modelling.

Research Applications

• Comparative kinetic analysis of short, medium and long trenbolone esters
• AR-binding and gene-expression mapping
• Anti-doping laboratory metabolite profiling
• Reference material for LC-MS/MS and GC-MS
• Structure–activity studies across trenbolone esters
• Endocrine-disruption and HPG-axis suppression modelling

Potential Research-Level Observations

• Strong anabolic signalling with high AR affinity
• Reduced extracellular water retention vs. aromatisable AAS
• Distinct multi-phase release behavior
• Useful for validating detection windows in doping labs

These refer to biochemical properties, not performance claims.

Safety Profile & Possible Risks

Androgenic / Virilisation

• Acne, seborrhoea, oily skin
• Accelerated hair loss
• Deepened voice, virilisation in females

Endocrine Effects

• Strong suppression of LH/FSH
• Lowered endogenous testosterone
• Impaired fertility, testicular atrophy

Cardiovascular & Metabolic

• Decreased HDL, increased LDL
• Potential hypertension
• Possible cardiomyopathy with prolonged exposure

Neuropsychological

Anxiety, irritability, mood instability

Insomnia (“tren sleep disturbance”)

Respiratory / Injection Issues

“Tren cough” episodes if oil enters bloodstream

Local irritation, post-injection discomfort

Toxicological Classification (SDS)

• Carcinogenic (H350)
• Reproductive toxicant (H360)
• Very toxic to aquatic organisms (H410)

Compliance & Regulatory

• Trenbolone esters are controlled substances in many jurisdictions
• WADA S1 Anabolic Agents – prohibited at all times
• Requires PPE, controlled storage and hazardous waste disposal
• Not a medicine, supplement or product for human administration

Technical Data Table

Intended Use

Research / Analytical / Non-medical

Research chemical — not for human or veterinary administration.